673 related articles for article (PubMed ID: 27967267)
1. Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).
McHardy SF; Wang HL; McCowen SV; Valdez MC
Expert Opin Ther Pat; 2017 Apr; 27(4):455-476. PubMed ID: 27967267
[TBL] [Abstract][Full Text] [Related]
2. Acetylcholinesterase inhibitors: a patent review (2008 - present).
Pohanka M
Expert Opin Ther Pat; 2012 Aug; 22(8):871-86. PubMed ID: 22768972
[TBL] [Abstract][Full Text] [Related]
3. Effect of reversible ligands on oxime-induced reactivation of sarin- and cyclosarin-inhibited human acetylcholinesterase.
Scheffel C; Thiermann H; Worek F
Toxicol Lett; 2015 Feb; 232(3):557-65. PubMed ID: 25522658
[TBL] [Abstract][Full Text] [Related]
4. Reactivators of acetylcholinesterase inhibited by organophosphorus nerve agents.
Mercey G; Verdelet T; Renou J; Kliachyna M; Baati R; Nachon F; Jean L; Renard PY
Acc Chem Res; 2012 May; 45(5):756-66. PubMed ID: 22360473
[TBL] [Abstract][Full Text] [Related]
5. Trends in the Recent Patent Literature on Cholinesterase Reactivators (2016-2019).
de Castro AA; Assis LC; Soares FV; Kuca K; Polisel DA; da Cunha EFF; Ramalho TC
Biomolecules; 2020 Mar; 10(3):. PubMed ID: 32178264
[TBL] [Abstract][Full Text] [Related]
6. Progress in acetylcholinesterase reactivators and in the treatment of organophosphorus intoxication: a patent review (2006-2016).
Gorecki L; Korabecny J; Musilek K; Nepovimova E; Malinak D; Kucera T; Dolezal R; Jun D; Soukup O; Kuca K
Expert Opin Ther Pat; 2017 Sep; 27(9):971-985. PubMed ID: 28569609
[TBL] [Abstract][Full Text] [Related]
7. Cholinesterase Inhibitors for Alzheimer's Disease: Multitargeting Strategy Based on Anti-Alzheimer's Drugs Repositioning.
Kabir MT; Uddin MS; Begum MM; Thangapandiyan S; Rahman MS; Aleya L; Mathew B; Ahmed M; Barreto GE; Ashraf GM
Curr Pharm Des; 2019; 25(33):3519-3535. PubMed ID: 31593530
[TBL] [Abstract][Full Text] [Related]
8. Interactions between xylene-linked carbamoyl bis-pyridinium mono-oximes and organophosphates inhibited-AChE: a kinetic study.
Sharma R; Gupta B; Acharya J; Kaushik MP; Ghosh KK
Toxicology; 2014 Feb; 316():1-8. PubMed ID: 24345352
[TBL] [Abstract][Full Text] [Related]
9. Novel nonquaternary reactivators showing reactivation efficiency for soman-inhibited human acetylcholinesterase.
Wei Z; Liu YQ; Wang YA; Li WH; Zhou XB; Zhao J; Huang CQ; Li XZ; Liu J; Zheng ZB; Li S
Toxicol Lett; 2016 Mar; 246():1-6. PubMed ID: 26809136
[TBL] [Abstract][Full Text] [Related]
10. Peripheral site ligand-oxime conjugates: A novel concept towards reactivation of nerve agent-inhibited human acetylcholinesterase.
de Koning MC; Joosen MJ; Noort D; van Zuylen A; Tromp MC
Bioorg Med Chem; 2011 Jan; 19(1):588-94. PubMed ID: 21112787
[TBL] [Abstract][Full Text] [Related]
11. Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain.
Rakonczay Z
Acta Biol Hung; 2003; 54(2):183-9. PubMed ID: 14535624
[TBL] [Abstract][Full Text] [Related]
12. Huprine X is a novel high-affinity inhibitor of acetylcholinesterase that is of interest for treatment of Alzheimer's disease.
Camps P; Cusack B; Mallender WD; El Achab RE; Morral J; Muñoz-Torrero D; Rosenberry TL
Mol Pharmacol; 2000 Feb; 57(2):409-17. PubMed ID: 10648652
[TBL] [Abstract][Full Text] [Related]
13. Peripheral site ligand conjugation to a non-quaternary oxime enhances reactivation of nerve agent-inhibited human acetylcholinesterase.
de Koning MC; van Grol M; Noort D
Toxicol Lett; 2011 Sep; 206(1):54-9. PubMed ID: 21504785
[TBL] [Abstract][Full Text] [Related]
14. Force spectroscopy between acetylcholine and single acetylcholinesterase molecules and the effects of inhibitors and reactivators studied by atomic force microscopy.
Yingge Z; Chunli B; Chen W; Delu Z
J Pharmacol Exp Ther; 2001 May; 297(2):798-803. PubMed ID: 11303072
[TBL] [Abstract][Full Text] [Related]
15. Molecular modelling and QSAR of reversible acetylcholines-terase inhibitors.
Kaur J; Zhang MQ
Curr Med Chem; 2000 Mar; 7(3):273-94. PubMed ID: 10637365
[TBL] [Abstract][Full Text] [Related]
16. NMR determination of Electrophorus electricus acetylcholinesterase inhibition and reactivation by neutral oximes.
da Cunha Xavier Soares SF; Vieira AA; Delfino RT; Figueroa-Villar JD
Bioorg Med Chem; 2013 Sep; 21(18):5923-30. PubMed ID: 23916150
[TBL] [Abstract][Full Text] [Related]
17. Cholinesterase inhibitors proposed for treating dementia in Alzheimer's disease: selectivity toward human brain acetylcholinesterase compared with butyrylcholinesterase.
Pacheco G; Palacios-Esquivel R; Moss DE
J Pharmacol Exp Ther; 1995 Aug; 274(2):767-70. PubMed ID: 7636741
[TBL] [Abstract][Full Text] [Related]
18. Can hydroxylamine be a more potent nucleophile for the reactivation of tabun-inhibited AChE than prototype oxime drugs? An answer derived from quantum chemical and steered molecular dynamics studies.
Lo R; Ganguly B
Mol Biosyst; 2014 Jul; 10(9):2368-83. PubMed ID: 24964273
[TBL] [Abstract][Full Text] [Related]
19. Anti-Neurodegenerative Benefits of Acetylcholinesterase Inhibitors in Alzheimer's Disease: Nexus of Cholinergic and Nerve Growth Factor Dysfunction.
Moss DE; Perez RG
Curr Alzheimer Res; 2021; 18(13):1010-1022. PubMed ID: 34911424
[TBL] [Abstract][Full Text] [Related]
20. Kinetic analysis of interactions of different sarin and tabun analogues with human acetylcholinesterase and oximes: is there a structure-activity relationship?
Aurbek N; Herkert NM; Koller M; Thiermann H; Worek F
Chem Biol Interact; 2010 Sep; 187(1-3):215-9. PubMed ID: 20105433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
